The ArthroCare ENT Plasma Wands are indicated for ablation of soft tissue and hemostasis of blood vessels in otorhinolaryngology (ENT) surgery including:

· Adenoidectomy
Cysts
· Head, Neck, Oral, and Sinus Surgery
Mastoidectomy
· Myringotomy with Effective Hemorrhage Control
· Nasal Airway Obstruction by Reduction of Hypertrophic Nasal Turbinates
Nasopharyngeal/Laryngeal Indications including Tracheal Polypectomy, and Laryngeal Lesion Debulking
Neck Mass
· Papilloma Keloids
· Submucosal Palatal Shrinkage
Submucosal Tissue Shrinkage
· Tonsillectomy (including palatine tonsils)
· Traditional Uvulopalatoplasty (RAUP)
Tumors
· Tissue in the Uvula/Soft Palate for the Treatment Of Snoring

Device Description

The ArthroCare ENT Plasma Wands are bipolar, high frequency electrosurgical devices designed for use in otorhinolaryngology (ENT) surgery. The Wands consists of a single or multiple active electrode(s) located on the distal end of the shaft, a suction line, a saline line, and an injection molded, medical grade plastic handle with integrated cable at the proximal end of the wand. A cable connector is attached to the end of the cable, which connects the wand directly to the ArthroCare Coblator II Controller (CII Controller). The EVac 70 Xtra and PROcise XP Wands with Integrated Cable (EVac 70 Xtra and PROcise XP Wands) are a part of the ENT Plasma Wand family previously cleared under 510(k) K070374 for a change in indications; the integrated cable design was first cleared under 510(k) K033257.

Consistent with the predicate cleared under 510(k) K070374, the ENT Plasma Wands are only compatible with the CII Controller. The controller is designed to deliver radiofrequency energy to the active electrode(s) at the distal end of the wand. Each Wand is designed for soft tissue procedures where tissue resection, ablation, coagulation, and hemostasis are desired. The Wands are provided sterile, and are intended for single use.

This 510(k) seeks clearance for the following changes:

트 Addition of an Electronic Use-Limiting (EUL) feature to the integrated cable which will limit the re-use of these single-use disposable Wands.
트 A change in the design of the cable connector which mates with the Controller.
트 Implementation of Ethylene Oxide (EO) sterilization in lieu of e-Beam sterilization.

AI/ML Overview

This document does not contain the detailed acceptance criteria or a study that precisely defines performance metrics with specific numerical targets. Instead, it is a 510(k) premarket notification summary for a medical device (ArthroCare ENT Plasma Wands) that seeks to establish substantial equivalence to a predicate device.

The core of this submission is to demonstrate that the modified device (EVac 70 Xtra and PROcise XP Wands with Integrated Cable) is as safe and effective as the previously cleared predicate device (ENT Plasma Wands, K070374), despite some minor changes.

Here's an attempt to extract and infer the information based on the provided text, while acknowledging that many specific details requested are not present in this type of FDA submission summary:

Table of Acceptance Criteria and Reported Device Performance

The document doesn't provide specific numerical acceptance criteria. Instead, it states that various tests "met the required specifications" or "perform as intended" or are "substantially equivalent."

Acceptance Criteria Category	Specific Criteria (Inferred from text)	Reported Device Performance
Functional Performance	Device operates as intended.	Met required specifications.
Ablation Life	Meets specified lifespan for ablation.	Met required specifications.
Coagulation	Achieves effective coagulation.	Met required specifications.
Software Testing	Software functions correctly.	Met required specifications.
Biocompatibility	Biocompatible with human tissue.	Met required specifications.
Electrical Safety	IEC 60601-2-2 compliant.	Met required specifications.
Tissue Effects (Ablation/Coagulation)	Comparable to predicate device.	Comparable to predicate devices in animal tissue.
Mechanical Properties	Acceptable for intended use.	Acceptable.
Safety and Efficacy	Equivalent to predicate device.	Not affected by modifications; substantially equivalent.
Sterilization	Effective sterilization using EO.	EO sterilization implemented.
Use-Limit Feature	Limits re-use of single-use wands.	Feature added to limit re-use.

2. Sample Size Used for the Test Set and Data Provenance

Sample Size: Not explicitly stated for specific tests. The performance data section vaguely mentions "animal tissue" for ablation and coagulation testing.
Data Provenance: "Animal tissue" is mentioned, implying in vivo or ex vivo animal studies. The country of origin is not specified but is implicitly within the scope of ArthroCare Corporation's operations (Austin, TX, USA). The studies are prospective in the sense that they were conducted for this 510(k) submission to demonstrate the equivalence of the modified device.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts

Not applicable. This document describes bench testing and animal tissue testing (likely performed by engineers/scientists), not studies requiring human expert adjudication of clinical outcomes or images for ground truth.

4. Adjudication Method for the Test Set

Not applicable. This was primarily bench and animal tissue testing, not a study requiring human adjudication.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done

No. This type of study is not mentioned as it is not typically required for a 510(k) submission seeking substantial equivalence for minor device modifications, especially when clinical data is explicitly stated as "not required."

6. If a Standalone (i.e. algorithm only without human-in-the-loop performance) was done

Not applicable. This device is a medical instrument (electrosurgical wand), not an AI algorithm. Its performance is inherent in its physical and functional characteristics.

7. The Type of Ground Truth Used

For the ablation and coagulation testing (the closest thing to a performance evaluation of its intended effect), the "ground truth" seems to be the observable tissue effects in animal tissue, which were then compared to the effects produced by the predicate device. The fundamental assumption is that if the new device produces similar tissue effects, it is equivalent.

8. The Sample Size for the Training Set

Not applicable. There is no training set mentioned, as this is a physical medical device and not an AI/machine learning system.

9. How the Ground Truth for the Training Set Was Established

Not applicable. No training set was used.

Summary

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the seal of the U.S. Department of Health and Human Services. The seal is circular and contains the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. In the center of the seal is an abstract image of three faces in profile, stacked on top of each other, resembling a stylized bird.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

November 19, 2014

ArthroCare Corporation Ms. Ashley Johnston Regulatory Affairs Specialist 7000 West William Cannon Drive Austin, Texas 78735

Re: K142999

Trade/Device Name: ArthroCare ENT Plasma Wands Regulation Number: 21 CFR 878.4400 Regulation Name: Electrosurgical cutting and coagulation device and accessories Regulatory Class: Class II Product Code: GEI Dated: October 15, 2014 Received: October 17, 2014

Dear Ms. Johnston:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical

{1}------------------------------------------------

device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

for

Sincerely yours,

David Krause -S

Binita S. Ashar, M.D., M.B.A., F.A.C.S. Director Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

510(k) Number (if known) K142999

Device Name ArthroCare ENT Plasma Wands

Indications for Use (Describe)

The ArthroCare ENT Plasma Wands are indicated for ablation of soft tissue and hemostasis of blood vessels in otorhinolaryngology (ENT) surgery including:

· Adenoidectomy
Cysts
· Head, Neck, Oral, and Sinus Surgery
Mastoidectomy
· Myringotomy with Effective Hemorrhage Control
· Nasal Airway Obstruction by Reduction of Hypertrophic Nasal Turbinates
Nasopharyngeal/Laryngeal Indications including Tracheal Polypectomy, and Laryngeal Lesion Debulking
Neck Mass
· Papilloma Keloids
· Submucosal Palatal Shrinkage
Submucosal Tissue Shrinkage
· Tonsillectomy (including palatine tonsils)
· Traditional Uvulopalatoplasty (RAUP)
Tumors
· Tissue in the Uvula/Soft Palate for the Treatment Of Snoring

Type of Use (Select one or both, as applicable)

|×| Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.

FOR FDA USE ONLY

Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)

{3}------------------------------------------------

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{4}------------------------------------------------

Image /page/4/Picture/0 description: The image shows the logo for ArthroCare. The logo consists of a stylized, abstract symbol on the left and the word "ArthroCare" in a bold, sans-serif font on the right. The symbol is made up of several curved lines, creating a sense of movement and flow.

510(k) Summary

ArthroCare Corporation

EVac 70 Xtra and PROcise XP Wands with Integrated Cable

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

General Information

Submitter Name:	ArthroCare Corporation
Address	7000 West William Cannon DriveAustin, TX 78735
Contact Person:	Ashley JohnstonRegulatory Affairs SpecialistPhone: 512-385-5762Fax: 512-895-1489
Date Prepared:	October 15, 2014
Device Name
Proprietary Name:	EVac 70 Xtra Wand with Integrated CablePROcise XP Wand with Integrated Cable
Common Name:	Electrosurgical devices and accessories
Classification Name:	Electrosurgical cutting and coagulation device and accessories
Device Class:	Class II
Product Code:	GEI
CFR Section:	21 CFR 878.4400

Predicate Device

ENT Plasma Wands EVac 70 Xtra Wand with Integrated Cable PROcise XP Wand with Integrated Cable

K070374 (April 25, 2007) K070374 (April 25, 2007)

Description

{5}------------------------------------------------

Image /page/5/Picture/0 description: The image shows the logo for ArthroCare. The logo consists of a stylized, abstract symbol on the left and the word "ArthroCare" on the right. The symbol is made up of several curved, parallel lines in a reddish-brown color, arranged in a circular or spherical shape. The word "ArthroCare" is written in a dark gray, sans-serif font, with the "A" slightly larger than the other letters. There is a registered trademark symbol to the upper right of the word "ArthroCare".

Coblator II Controller (CII Controller). The EVac 70 Xtra and PROcise XP Wands with Integrated Cable (EVac 70 Xtra and PROcise XP Wands) are a part of the ENT Plasma Wand family previously cleared under 510(k) K070374 for a change in indications; the integrated cable design was first cleared under 510(k) K033257.

This 510(k) seeks clearance for the following changes:

트 Addition of an Electronic Use-Limiting (EUL) feature to the integrated cable which will limit the re-use of these single-use disposable Wands.
트 A change in the design of the cable connector which mates with the Controller.
트 Implementation of Ethylene Oxide (EO) sterilization in lieu of e-Beam sterilization.

Intended Use/Indications For Use

The ArthroCare ENT Plasma Wands are indicated for ablation, resection, and coagulation of soft tissue and hemostasis of blood vessels in otorhinolarvngology (ENT) surgery including adenoidectomy, cysts, head, neck, oral, and sinus surgery, mastoidectomy, myringotomy with effective hemorrhage control, nasal airway obstruction of hypertrophic nasal turbinates, nasopharyngeal/laryngeal indications including tracheal procedures, laryngeal polypectomy, and laryngeal lesion debulking, neck mass, papilloma keloids, submucosal palatal shrinkage, submucosal tissue shrinkage, tonsillectomy (including palatine tonsils), traditional uvulopalatoplasty (RAUP), tumors, tissue in the uvula/soft palate for the treatment of snoring.

Summary of Technological Characteristics

No changes or modifications have been made to the distal Wand elements (i.e. electrodes, materials, shaft, and insulation), indications for use, technology, or principle of operation previously cleared in 510(k) K070374. The following table represents a summary of the technological characteristics of the modified ENT Plasma Wands.

	PREDICATE DEVICE:	PROPOSED DEVICE:
	ENT Plasma Wands (K070374)	Modified ENT Plasma Wands■ EVac 70 Xtra Wand with IC■ PROcise XP Wand with IC
Intended Use	The ArthroCare ENT Plasma Wands are intended for ablation, resection, and coagulation of soft tissue and hemostasis of blood vessels in otorhinolaryngology (ENT) surgery.	Same
Patient Usage	Single Use	Same
Sterilization	Radiation	EO
ElectricalSafety/EMC	IEC 60601-2-2 compliant	Same
Use-limit Feature	No	Yes

{6}------------------------------------------------

Image /page/6/Picture/0 description: The image shows the logo for ArthroCare. The logo consists of a stylized red symbol on the left and the word "ArthroCare" in black on the right. The symbol is made up of several curved lines that form a circular shape. The word "ArthroCare" is written in a sans-serif font, and there is a trademark symbol after the word.

Cable connectordesign	Press-fit	Snap-fit
---------------------------	-----------	----------

Performance Data

Performance bench testing, including functional testing, ablation life, coagulation, software testing, biocompatibility, and electrical safety testing were performed on the proposed EVac 70 Xtra and PROcise XP Wands with Integrated Cable, which demonstrated the new cable assembly met the required specifications.

Ablation and coagulation testing were performed in animal tissue to compare the tissue effects using the modified Wands as compared to the predicate devices to support substantial equivalence. No clinical data is required to support the proposed change.

Summary

All testing demonstrates that the EVac 70 Xtra and PROcise XP Wands with Integrated Cable perform as intended and have acceptable mechanical properties when used in accordance with its labeling.

As the intended use, operating principle, materials and technological characteristics are unchanged from the predicate devices, the EVac 70 Xtra and PROcise XP Wands with Integrated Cable are substantially equivalent. The modifications to the design and sterilization method do not affect the safety or efficacy of the devices.

Regulation Number and Section

§ 878.4400 Electrosurgical cutting and coagulation device and accessories.

(a)
Identification. An electrosurgical cutting and coagulation device and accessories is a device intended to remove tissue and control bleeding by use of high-frequency electrical current.(b)
Classification. Class II.